Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies (NYSE: BHC) announced participation in three investor conferences in March 2021. Key executives, including Chairman Joseph C. Papa and CFO Paul S. Herendeen, will represent the company at:

• Cowen & Co. Health Care Conference on March 1 at 11:00 a.m. ET
• J.P. Morgan Global High Yield & Leveraged Finance Conference on March 3 at 8:30 a.m. ET
• Barclays Global Healthcare Conference on March 9 at 2:25 p.m. ET

Live webcasts will be available on Bausch Health's Investor Relations page.

Bausch Health Companies Inc. (NYSE/TSX: BHC) responded to Icahn Capital LP's Schedule 13D filing, emphasizing their commitment to enhancing shareholder value through open communication. The company plans to spin off Bausch + Lomb to unlock additional value. Bausch Health reported a strong end to 2020, exceeding $2.2 billion in revenue and delivering robust adjusted EBITDA and cash flow. The firm remains focused on its COVID-19 recovery plan and aims to improve EBITDA and working capital while reducing leverage.

Bausch Health Companies Inc. announced that VYZULTA^® (latanoprostene bunod ophthalmic solution, 0.024%) has received regulatory approval from South Korea's Ministry of Food and Drug Safety. VYZULTA is designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is now approved in nine markets, including the U.S., Canada, and Mexico. Thomas J. Appio emphasizes the company's commitment to securing additional global approvals for innovative eye health treatments.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched its 2021 Aspire Higher scholarship program, which awards scholarships of up to $10,000 to nine students who have experienced dermatologic conditions. Since its inception in 2013, the program has provided $738,000 to 51 students. Applicants can submit their applications until May 31, 2021, with winners announced in July 2021. The initiative aims to support students managing the challenges of education alongside skin conditions during the pandemic, highlighting the commitment of Bausch Health to enhance educational opportunities for affected students.

Bausch Health (BHC) and Prevent Blindness are launching a year-long video series during AMD Awareness Month to raise awareness about Age-Related Macular Degeneration (AMD), affecting around 16 million Americans. This marks the sixth consecutive year of their collaboration. The campaign will feature real-life stories of individuals managing AMD and will include a social media donation initiative, contributing $1 for each share or like on relevant Facebook posts, up to $50,000. The initiative aims to educate the public on AMD while encouraging eye examinations.

Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its fourth-quarter and full-year 2020 financial results on February 24, 2021. The company will hold a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can access the call through the company's Investor Relations section on its website, where all related materials will be available prior to the call.

Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), announced on January 21, 2021, that its LUMIFY® redness reliever eye drops received approval from South Korea's Ministry of Food and Drug Safety. This adds to LUMIFY's global presence, following its success in the U.S. where it holds a 40% market share among redness relievers. LUMIFY is expected to be available in South Korea in the second half of 2021, with additional regulatory submissions ongoing in multiple countries.

Bausch + Lomb announced that it will present data on its Bausch + Lomb INFUSE silicone hydrogel daily disposable contact lenses at the virtual Global Specialty Lens Symposium from Jan. 21-23, 2021. During this event, Bausch + Lomb will also discuss fitting efficiencies for its Zenlens™ scleral lenses. A survey reported that 97% of patients experienced crisp, clear vision with INFUSE lenses, and 94% agreed they help maintain moisture. Two poster presentations will focus on the lenses' impact on tear film protein and water stability.

Bausch Health announced the publication of a Phase 2 study in Cornea, demonstrating that NOV03, an investigational treatment for Dry Eye Disease (DED) related to Meibomian gland dysfunction, met its primary efficacy endpoint. The study enrolled 336 patients and exhibited significant improvements in corneal staining and symptoms like dryness and burning. Additionally, the first of two Phase 3 studies evaluating NOV03 has been fully enrolled with 599 participants. These developments position NOV03 as a potential first-in-class treatment for millions suffering from symptomatic DED.